消化不良治療薬市場：タイプ別、薬剤タイプ別、流通チャネル別-2025-2030年の世界予測

消化不良治療薬市場は、2023年に85億8,000万米ドルと評価され、2024年には90億1,000万米ドルに達すると予測され、CAGR 5.12％で成長し、2030年には121億8,000万米ドルに達すると予測されています。

消化器疾患治療薬は、胃の不快感、膨満感、吐き気などの症状を管理することを目的とした、より広範な消化器疾患治療薬市場の中で重要なセグメントを形成しています。これらの薬剤の必要性は、食生活の乱れやストレスなどのライフスタイル要因によって悪化する機能性ディスペプシアの世界の有病率の高さによって強調されています。これらの薬剤は、病院、診療所、在宅医療のあらゆる場面で応用され、短期的な症状の緩和と慢性疾患の長期的な管理の両方に役立っています。市場成長の主な促進要因としては、人口の高齢化、胃腸疾患の罹患率の上昇、製剤およびドラッグデリバリーシステムの進歩などが挙げられます。新興市場におけるヘルスケアに対する認識とアクセスの高まりも、市場拡大のための肥沃な土壌となっています。より効能の高い新規化合物の開発や、市販薬も含めた患者中心のソリューションの開発が大きなビジネスチャンスであり、利用しやすいヘルスケアを求める消費者の嗜好の高まりを利用できる可能性があります。しかし、医薬品開発の高コスト、厳しい規制プロセス、潜在的な副作用などの制約が大きな課題となっています。さらに、代替療法や栄養補助食品との競合も市場成長の妨げとなっています。これらの課題を克服するためには、技術革新は精密医療と、AI主導の診断や個別化された治療計画などのデジタルヘルス技術の統合に重点を置くべきであり、それによって薬効と患者のアドヒアランスを高めることができます。ホリスティック・ヘルスケア・ソリューションに対する需要の高まりを考慮すれば、プロバイオティクスや天然抽出物によって医薬品ポートフォリオを多様化するための強固な研究開発戦略への投資は、戦略的な軸となり得ると思われます。市場力学はダイナミックで競争が激しいため、医療従事者や患者と継続的に関わり、満たされていないニーズを特定し、進化する消費者の嗜好に適応する必要があります。優位性を維持するために、企業は消費者教育に投資し、よりスムーズな市場参入と拡大を促進するために、規制機関との強力な協力関係を構築すべきです。

市場力学：急速に進化する消化不良治療薬市場の主要市場インサイトを公開

消化不良治療薬市場は、需要と供給のダイナミックな相互作用によって変貌を遂げています。このような市場力学の進化を理解することで、企業は十分な情報に基づいた投資決定、戦略的決定の精緻化、そして新たなビジネスチャンスの獲得に備えることができます。これらの動向を包括的に把握することで、企業は政治的、地理的、技術的、社会的、経済的な領域にわたる様々なリスクを軽減することができ、また、消費者行動とそれが製造コストや購買動向に与える影響をより明確に理解することができます。

• 市場促進要因
  • 世界中で急増する消化不良の有病率
  • 迅速な医薬品承認プロセスを支持する政府の政策
  • ドラッグデリバリーおよび包装技術の改善への投資
• 市場抑制要因
  • 製品回収と安全性への懸念
• 市場機会
  • 共同開発や官民パートナーシップによる開発拡大
  • 薬効向上のための研究開発の進展
• 市場の課題
  • 偽造医薬品の入手可能性

ポーターのファイブフォース：消化不良治療薬市場をナビゲートする戦略ツール

ポーターのファイブフォースフレームワークは、市場情勢の競合情勢を理解するための重要なツールです。ポーターのファイブフォース・フレームワークは、企業の競争力を評価し、戦略的機会を探るための明確な手法を提供します。このフレームワークは、企業が市場内の勢力図を評価し、新規事業の収益性を判断するのに役立ちます。これらの洞察により、企業は自社の強みを活かし、弱みに対処し、潜在的な課題を回避することができ、より強靭な市場でのポジショニングを確保することができます。

PESTLE分析：消化不良治療薬市場における外部からの影響の把握

外部マクロ環境要因は、消化不良治療薬市場の業績ダイナミクスを形成する上で極めて重要な役割を果たします。政治的、経済的、社会的、技術的、法的、環境的要因の分析は、これらの影響をナビゲートするために必要な情報を提供します。PESTLE要因を調査することで、企業は潜在的なリスクと機会をよりよく理解することができます。この分析により、企業は規制、消費者の嗜好、経済動向の変化を予測し、先を見越した積極的な意思決定を行う準備ができます。

市場シェア分析消化不良治療薬市場における競合情勢の把握

消化不良治療薬市場の詳細な市場シェア分析により、ベンダーの業績を包括的に評価することができます。企業は、収益、顧客ベース、成長率などの主要指標を比較することで、競争上のポジショニングを明らかにすることができます。この分析により、市場の集中、断片化、統合の動向が明らかになり、ベンダーは競争が激化する中で自社の地位を高める戦略的意思決定を行うために必要な知見を得ることができます。

FPNVポジショニング・マトリックス消化不良治療薬市場におけるベンダーのパフォーマンス評価

FPNVポジショニングマトリックスは、消化不良治療薬市場においてベンダーを評価するための重要なツールです。このマトリックスにより、ビジネス組織はベンダーのビジネス戦略と製品満足度に基づき評価することで、目標に沿った十分な情報に基づいた意思決定を行うことができます。4つの象限によってベンダーを明確かつ正確にセグメント化し、戦略目標に最適なパートナーやソリューションを特定することができます。

戦略分析と推奨消化不良治療薬市場における成功への道筋を描く

消化不良治療薬市場の戦略分析は、世界市場でのプレゼンス強化を目指す企業にとって不可欠です。主要なリソース、能力、業績指標を見直すことで、企業は成長機会を特定し、改善に取り組むことができます。このアプローチにより、競合情勢における課題を克服し、新たなビジネスチャンスを活かして長期的な成功を収めるための体制を整えることができます。

本レポートでは、主要な注目分野を網羅した市場の包括的な分析を提供しています：

1.市場の浸透度：現在の市場環境の詳細なレビュー、主要企業による広範なデータ、市場でのリーチと全体的な影響力の評価。

2.市場の開拓度：新興市場における成長機会を特定し、既存分野における拡大可能性を評価し、将来の成長に向けた戦略的ロードマップを提供します。

3.市場の多様化：最近の製品発売、未開拓の地域、業界の主要な進歩、市場を形成する戦略的投資を分析します。

4.競合の評価と情報：競合情勢を徹底的に分析し、市場シェア、事業戦略、製品ポートフォリオ、認証、規制当局の承認、特許動向、主要企業の技術進歩などを検証します。

5.製品開発およびイノベーション：将来の市場成長を促進すると期待される最先端技術、研究開発活動、製品イノベーションをハイライトしています。

また、利害関係者が十分な情報を得た上で意思決定できるよう、重要な質問にも答えています：

1.現在の市場規模と今後の成長予測は？

2.最高の投資機会を提供する製品、セグメント、地域はどこか？

3.市場を形成する主な技術動向と規制の影響とは？

4.主要ベンダーの市場シェアと競合ポジションは？

5.ベンダーの市場参入・撤退戦略の原動力となる収益源と戦略的機会は何か？

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

• 市場力学
  • 促進要因
    • 世界中で消化不良の有病率が急増
    • 医薬品の承認手続きの迅速化を支持する政府の政策
    • ドラッグデリバリーおよび包装技術の改善への投資
  • 抑制要因
    • 製品リコールと安全性に関する懸念
  • 機会
    • 共同開発と官民連携による拡大
    • 薬効向上のための研究開発の進歩
  • 課題
    • 偽造医薬品の入手可能性
• 市場セグメンテーション分析
  • タイプ：機能性ディスペプシアの広範な発生と、より個別化された医薬品への移行
  • 薬剤の種類：消化不良治療におけるプロトンポンプ阻害薬とH2受容体遮断薬の利用増加
• ポーターのファイブフォース分析
• PESTEL分析
  • 政治的
  • 経済
  • 社交
  • 技術的
  • 法律上
  • 環境

第6章 消化不良治療薬市場：タイプ別

• 機能性消化不良
• 有機性消化不良

第7章 消化不良治療薬市場薬の種類別

• 酸抑制剤
• 制酸剤
• 抗生物質
• 抗けいれん薬
• 抗うつ薬
• シメチジン
• ファモチジン
• H2拮抗薬
• ニザチジン
• 消化促進剤
• プロトンポンプ阻害剤
• ラベプラゾール
• ザンタック

第8章 消化不良治療薬市場：流通チャネル別

• 病院薬局
• オンライン薬局
• 小売薬局

第9章 南北アメリカの消化不良治療薬市場

• アルゼンチン
• ブラジル
• カナダ
• メキシコ
• 米国

第10章 アジア太平洋地域の消化不良治療薬市場

• オーストラリア
• 中国
• インド
• インドネシア
• 日本
• マレーシア
• フィリピン
• シンガポール
• 韓国
• 台湾
• タイ
• ベトナム

第11章 欧州・中東・アフリカの消化不良治療薬市場

• デンマーク
• エジプト
• フィンランド
• フランス
• ドイツ
• イスラエル
• イタリア
• オランダ
• ナイジェリア
• ノルウェー
• ポーランド
• カタール
• ロシア
• サウジアラビア
• 南アフリカ
• スペイン
• スウェーデン
• スイス
• トルコ
• アラブ首長国連邦
• 英国

第12章 競合情勢

• 市場シェア分析2023
• FPNVポジショニングマトリックス, 2023
• 競合シナリオ分析
  • 画期的なFDA承認、ファトムファーマシューティカルズがびらん性GERD治療薬VOQUEZNAを発表
  • アップシャー・スミスのファモチジン経口懸濁液の発売は、米国のジェネリック医薬品市場における戦略的動きです。
  • マークサンズ・ファーマ、ジェネリックファモチジン錠の米国FDA承認を取得
• 戦略分析と提言

企業一覧

• Abbott Laboratories
• ANI Pharmaceuticals, Inc.
• AstraZeneca PLC
• Bayer AG
• Cadila Pharmaceuticals
• Dr Reddy's Laboratories Ltd
• Haleon PLC
• Intas Pharmaceuticals Ltd.
• Lupin Ltd.
• Mankind Pharma
• Pfizer Inc.
• Prestige Consumer Healthcare Inc.
• Procter & Gamble Company
• Salix Pharmaceuticals, Inc. by Valeant Pharmaceuticals International
• Sanofi SA
• Sun Pharmaceutical Industries Ltd.
• Takeda Pharmaceutical Company Limited
• Themis Medicare Ltd.
• Torrent Pharmaceuticals Ltd.

LIST OF FIGURES

• FIGURE 1. DYSPEPSIA DRUG MARKET RESEARCH PROCESS
• FIGURE 2. DYSPEPSIA DRUG MARKET SIZE, 2023 VS 2030
• FIGURE 3. GLOBAL DYSPEPSIA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• FIGURE 4. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 5. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 6. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2023 VS 2030 (%)
• FIGURE 7. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 8. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2023 VS 2030 (%)
• FIGURE 9. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 10. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2030 (%)
• FIGURE 11. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 12. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 13. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 14. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2023 VS 2030 (%)
• FIGURE 15. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 16. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 17. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 18. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
• FIGURE 19. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
• FIGURE 20. DYSPEPSIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
• FIGURE 21. DYSPEPSIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

• TABLE 1. DYSPEPSIA DRUG MARKET SEGMENTATION & COVERAGE
• TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
• TABLE 3. GLOBAL DYSPEPSIA DRUG MARKET SIZE, 2018-2030 (USD MILLION)
• TABLE 4. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 5. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 6. DYSPEPSIA DRUG MARKET DYNAMICS
• TABLE 7. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 8. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY FUNCTIONAL DYSPEPSIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 9. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ORGANIC DYSPEPSIA, BY REGION, 2018-2030 (USD MILLION)
• TABLE 10. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 11. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ACID REDUCER, BY REGION, 2018-2030 (USD MILLION)
• TABLE 12. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTACIDS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 13. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTIBIOTICS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 14. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTICONVULSANT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 15. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ANTIDEPRESSANTS, BY REGION, 2018-2030 (USD MILLION)
• TABLE 16. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY CIMETIDINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 17. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY FAMOTIDINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 18. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY H2 ANTAGONIST, BY REGION, 2018-2030 (USD MILLION)
• TABLE 19. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY NIZATIDINE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 20. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROKINETIC AGENT, BY REGION, 2018-2030 (USD MILLION)
• TABLE 21. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY PROTON-PUMP INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
• TABLE 22. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RABEPRAZOLE, BY REGION, 2018-2030 (USD MILLION)
• TABLE 23. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ZANTAC, BY REGION, 2018-2030 (USD MILLION)
• TABLE 24. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 25. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY HOSPITAL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 26. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY ONLINE PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 27. GLOBAL DYSPEPSIA DRUG MARKET SIZE, BY RETAIL PHARMACIES, BY REGION, 2018-2030 (USD MILLION)
• TABLE 28. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 29. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 30. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 31. AMERICAS DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 32. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 33. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 34. ARGENTINA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 35. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 36. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 37. BRAZIL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 38. CANADA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 39. CANADA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 40. CANADA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 41. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 42. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 43. MEXICO DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 44. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 45. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 46. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 47. UNITED STATES DYSPEPSIA DRUG MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
• TABLE 48. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 49. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 50. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 51. ASIA-PACIFIC DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 52. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 53. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 54. AUSTRALIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 55. CHINA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 56. CHINA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 57. CHINA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 58. INDIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 59. INDIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 60. INDIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 61. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 62. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 63. INDONESIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 64. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 65. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 66. JAPAN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 67. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 68. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 69. MALAYSIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 70. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 71. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 72. PHILIPPINES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 73. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 74. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 75. SINGAPORE DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 76. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 77. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 78. SOUTH KOREA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 79. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 80. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 81. TAIWAN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 82. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 83. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 84. THAILAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 85. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 86. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 87. VIETNAM DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 88. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 89. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 90. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 91. EUROPE, MIDDLE EAST & AFRICA DYSPEPSIA DRUG MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
• TABLE 92. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 93. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 94. DENMARK DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 95. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 96. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 97. EGYPT DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 98. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 99. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 100. FINLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 101. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 102. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 103. FRANCE DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 104. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 105. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 106. GERMANY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 107. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 108. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 109. ISRAEL DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 110. ITALY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 111. ITALY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 112. ITALY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 113. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 114. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 115. NETHERLANDS DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 116. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 117. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 118. NIGERIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 119. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 120. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 121. NORWAY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 122. POLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 123. POLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 124. POLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 125. QATAR DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 126. QATAR DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 127. QATAR DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 128. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 129. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 130. RUSSIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 131. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 132. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 133. SAUDI ARABIA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 134. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 135. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 136. SOUTH AFRICA DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 137. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 138. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 139. SPAIN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 140. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 141. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 142. SWEDEN DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 143. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 144. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 145. SWITZERLAND DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 146. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 147. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 148. TURKEY DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 149. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 150. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 151. UNITED ARAB EMIRATES DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 152. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY TYPE, 2018-2030 (USD MILLION)
• TABLE 153. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY DRUG TYPE, 2018-2030 (USD MILLION)
• TABLE 154. UNITED KINGDOM DYSPEPSIA DRUG MARKET SIZE, BY DISTRIBUTION CHANNEL, 2018-2030 (USD MILLION)
• TABLE 155. DYSPEPSIA DRUG MARKET SHARE, BY KEY PLAYER, 2023
• TABLE 156. DYSPEPSIA DRUG MARKET, FPNV POSITIONING MATRIX, 2023

The Dyspepsia Drug Market was valued at USD 8.58 billion in 2023, expected to reach USD 9.01 billion in 2024, and is projected to grow at a CAGR of 5.12%, to USD 12.18 billion by 2030.

Dyspepsia drugs form a crucial segment within the broader gastrointestinal therapeutics market, aimed at managing symptoms like stomach discomfort, bloating, and nausea. The necessity for these drugs is underscored by the high prevalence of functional dyspepsia worldwide, exacerbated by lifestyle factors such as poor diet and stress. These drugs find applications across hospitals, clinics, and homecare settings, serving both short-term symptomatic relief and long-term management of chronic conditions. Key drivers of market growth include an aging population, the rising incidence of gastrointestinal disorders, and ongoing advancements in drug formulations and delivery systems. Increasing healthcare awareness and access in emerging markets also provide fertile ground for market expansion. A prominent opportunity lies in the development of novel, more efficacious drug compounds and patient-centered solutions, including over-the-counter options, potentially tapping into the growing consumer preference for accessible healthcare solutions. However, limitations like the high cost of drug development, stringent regulatory processes, and potential side effects pose significant challenges. Additionally, market growth is hampered by competition from alternative therapies and dietary supplements. To overcome these challenges, innovation should focus on precision medicine and the integration of digital health technologies, such as AI-driven diagnostics and personalized treatment plans, thus enhancing drug efficacy and patient adherence. Investing in robust R&D strategies to diversify the drug portfolio with probiotics and natural extracts could be a strategic pivot, considering the rising demand for holistic healthcare solutions. The nature of the dyspepsia drug market is dynamic and competitive, necessitating continuous engagement with healthcare professionals and patients to identify unmet needs and adapt to evolving consumer preferences. To maintain an edge, companies should invest in consumer education and build strong collaborations with regulatory bodies to facilitate smoother market entry and expansion.

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving Dyspepsia Drug Market

The Dyspepsia Drug Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

• Market Drivers
  • Surging prevalence of Dyspepsia worldwide
  • Government policies favoring faster drug approval processes
  • Investment in improved drug delivery and packaging technologies
• Market Restraints
  • Product recall and safety concerns
• Market Opportunities
  • Expansion through collaborative development and public-private partnerships
  • Advancements in research and development for enhanced drug efficacy
• Market Challenges
  • Availability of the counterfeit drugs

Porter's Five Forces: A Strategic Tool for Navigating the Dyspepsia Drug Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the Dyspepsia Drug Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the Dyspepsia Drug Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the Dyspepsia Drug Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the Dyspepsia Drug Market

A detailed market share analysis in the Dyspepsia Drug Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the Dyspepsia Drug Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the Dyspepsia Drug Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the Dyspepsia Drug Market

A strategic analysis of the Dyspepsia Drug Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the Dyspepsia Drug Market, highlighting leading vendors and their innovative profiles. These include Abbott Laboratories, ANI Pharmaceuticals, Inc., AstraZeneca PLC, Bayer AG, Cadila Pharmaceuticals, Dr Reddy's Laboratories Ltd, Haleon PLC, Intas Pharmaceuticals Ltd., Lupin Ltd., Mankind Pharma, Pfizer Inc., Prestige Consumer Healthcare Inc., Procter & Gamble Company, Salix Pharmaceuticals, Inc. by Valeant Pharmaceuticals International, Sanofi SA, Sun Pharmaceutical Industries Ltd., Takeda Pharmaceutical Company Limited, Themis Medicare Ltd., and Torrent Pharmaceuticals Ltd..

Market Segmentation & Coverage

This research report categorizes the Dyspepsia Drug Market to forecast the revenues and analyze trends in each of the following sub-markets:

• Based on Type, market is studied across Functional Dyspepsia and Organic Dyspepsia.
• Based on Drug Type, market is studied across Acid Reducer, Antacids, Antibiotics, Anticonvulsant, Antidepressants, Cimetidine, Famotidine, H2 Antagonist, Nizatidine, Prokinetic agent, Proton-pump Inhibitor, Rabeprazole, and Zantac.
• Based on Distribution Channel, market is studied across Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies.
• Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Segmentation & Coverage
• 1.3. Years Considered for the Study
• 1.4. Currency & Pricing
• 1.5. Language
• 1.6. Stakeholders

2. Research Methodology

• 2.1. Define: Research Objective
• 2.2. Determine: Research Design
• 2.3. Prepare: Research Instrument
• 2.4. Collect: Data Source
• 2.5. Analyze: Data Interpretation
• 2.6. Formulate: Data Verification
• 2.7. Publish: Research Report
• 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

• 5.1. Market Dynamics
  • 5.1.1. Drivers
    • 5.1.1.1. Surging prevalence of Dyspepsia worldwide
    • 5.1.1.2. Government policies favoring faster drug approval processes
    • 5.1.1.3. Investment in improved drug delivery and packaging technologies
  • 5.1.2. Restraints
    • 5.1.2.1. Product recall and safety concerns
  • 5.1.3. Opportunities
    • 5.1.3.1. Expansion through collaborative development and public-private partnerships
    • 5.1.3.2. Advancements in research and development for enhanced drug efficacy
  • 5.1.4. Challenges
    • 5.1.4.1. Availability of the counterfeit drugs
• 5.2. Market Segmentation Analysis
  • 5.2.1. Type: Wide occurrence of functional dyspepsia with the shift towards more personalized drugs
  • 5.2.2. Drug Type: Growing utilization of proton pump inhibitors and H2 receptor blockers for dyspepsia treatment
• 5.3. Porter's Five Forces Analysis
  • 5.3.1. Threat of New Entrants
  • 5.3.2. Threat of Substitutes
  • 5.3.3. Bargaining Power of Customers
  • 5.3.4. Bargaining Power of Suppliers
  • 5.3.5. Industry Rivalry
• 5.4. PESTLE Analysis
  • 5.4.1. Political
  • 5.4.2. Economic
  • 5.4.3. Social
  • 5.4.4. Technological
  • 5.4.5. Legal
  • 5.4.6. Environmental

6. Dyspepsia Drug Market, by Type

• 6.1. Introduction
• 6.2. Functional Dyspepsia
• 6.3. Organic Dyspepsia

7. Dyspepsia Drug Market, by Drug Type

• 7.1. Introduction
• 7.2. Acid Reducer
• 7.3. Antacids
• 7.4. Antibiotics
• 7.5. Anticonvulsant
• 7.6. Antidepressants
• 7.7. Cimetidine
• 7.8. Famotidine
• 7.9. H2 Antagonist
• 7.10. Nizatidine
• 7.11. Prokinetic agent
• 7.12. Proton-pump Inhibitor
• 7.13. Rabeprazole
• 7.14. Zantac

8. Dyspepsia Drug Market, by Distribution Channel

• 8.1. Introduction
• 8.2. Hospital Pharmacies
• 8.3. Online Pharmacies
• 8.4. Retail Pharmacies

9. Americas Dyspepsia Drug Market

• 9.1. Introduction
• 9.2. Argentina
• 9.3. Brazil
• 9.4. Canada
• 9.5. Mexico
• 9.6. United States

10. Asia-Pacific Dyspepsia Drug Market

• 10.1. Introduction
• 10.2. Australia
• 10.3. China
• 10.4. India
• 10.5. Indonesia
• 10.6. Japan
• 10.7. Malaysia
• 10.8. Philippines
• 10.9. Singapore
• 10.10. South Korea
• 10.11. Taiwan
• 10.12. Thailand
• 10.13. Vietnam

11. Europe, Middle East & Africa Dyspepsia Drug Market

• 11.1. Introduction
• 11.2. Denmark
• 11.3. Egypt
• 11.4. Finland
• 11.5. France
• 11.6. Germany
• 11.7. Israel
• 11.8. Italy
• 11.9. Netherlands
• 11.10. Nigeria
• 11.11. Norway
• 11.12. Poland
• 11.13. Qatar
• 11.14. Russia
• 11.15. Saudi Arabia
• 11.16. South Africa
• 11.17. Spain
• 11.18. Sweden
• 11.19. Switzerland
• 11.20. Turkey
• 11.21. United Arab Emirates
• 11.22. United Kingdom

12. Competitive Landscape

• 12.1. Market Share Analysis, 2023
• 12.2. FPNV Positioning Matrix, 2023
• 12.3. Competitive Scenario Analysis
  • 12.3.1. Breakthrough FDA Approval, Phathom Pharmaceuticals Unveils VOQUEZNA for Erosive GERD Treatment
  • 12.3.2. Launch of Upsher-Smith's Famotidine for Oral Suspension, A Strategic Move in the U.S. Generic Drug Market
  • 12.3.3. Marksans Pharma Secures USFDA Approval for Generic Famotidine Tablets
• 12.4. Strategy Analysis & Recommendation

Companies Mentioned

• 1. Abbott Laboratories
• 2. ANI Pharmaceuticals, Inc.
• 3. AstraZeneca PLC
• 4. Bayer AG
• 5. Cadila Pharmaceuticals
• 6. Dr Reddy's Laboratories Ltd
• 7. Haleon PLC
• 8. Intas Pharmaceuticals Ltd.
• 9. Lupin Ltd.
• 10. Mankind Pharma
• 11. Pfizer Inc.
• 12. Prestige Consumer Healthcare Inc.
• 13. Procter & Gamble Company
• 14. Salix Pharmaceuticals, Inc. by Valeant Pharmaceuticals International
• 15. Sanofi SA
• 16. Sun Pharmaceutical Industries Ltd.
• 17. Takeda Pharmaceutical Company Limited
• 18. Themis Medicare Ltd.
• 19. Torrent Pharmaceuticals Ltd.